A Phase 2 Study of Abemaciclib in Patients (PTS) with Brain Metastases (BM) Secondary to HR+, HER2-Metastatic Breast Cancer (MBC)

被引：0
作者：
Anders, Carey [1 ]
Le Rhun, Emily [2 ]
Bachelot, Thomas [3 ]
Yardley, Denise [4 ]
Awade, Ahmad [5 ]
Conte, Pierre Franco [6 ]
Cabos, Peter [7 ]
Bear, Melissa [8 ]
Tolaney, Sarah [9 ]
机构：
[1] Duke Canc Inst, Durham, NC USA
[2] Univ Hosp, Lille, France
[3] Ctr Leon Berard, Lyon, France
[4] Sarah Cannon Res Inst, Nashville, TN USA
[5] Inst Jules Bordet, Brussels, Belgium
[6] Univ Padua, Padua, Italy
[7] Univ Denver, Denver, CO USA
[8] Elli Lilly, Indianapolis, IN USA
[9] Dana Farber Canc Inst, Boston, MA 02115 USA
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2020年 / 43卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
168
引用
收藏
页码：10 / 10
页数：1
相关论文
共 50 条
  • [41] FDA Approves Sacituzumab Govitecan for Pretreated HR+/HER2-Metastatic Breast Cancer
    不详
    AMERICAN JOURNAL OF MANAGED CARE, 2023, 29 (04) : SP315 - SP315
  • [42] Phase II study of nivolumab in combination with abemaciclib plus endocrine therapy in patients with HR+, HER2-metastatic breast cancer: WJOG11418B NEWFLAME trial
    Masuda, Jun
    Tsurutani, Junji
    Masuda, Norikazu
    Tanabe, Yuko
    Iwasa, Tsutomu
    Takahashi, Masato
    Futamura, Manabu
    Matsumoto, Koji
    Aogi, Kenjiro
    Iwata, Hiroji
    Hosonaga, Mari
    Mukohara, Toru
    Yoshimura, Kenichi
    Takano, Toshimi
    CANCER RESEARCH, 2021, 81 (04)
  • [43] Real-world experience with CDK4/6 inhibitors for HR+/HER2-metastatic breast cancer (MBC)
    Abdallah, H. M. A.
    Owoseni, Y. I.
    Sultan, A.
    Ahmed, S.
    Wood, J.
    Varadhan, B.
    Ayodele, O.
    ANNALS OF ONCOLOGY, 2023, 34 : S369 - S370
  • [44] Association between PIK3CA mutation status and development of brain metastases in HR+/HER2-metastatic breast cancer
    Fitzgerald, D. M.
    Muzikansky, A.
    Pinto, C.
    Henderson, L.
    Walmsley, C.
    Allen, R.
    Ferraro, G. B.
    Isakoff, S.
    Moy, B.
    Oh, K.
    Shih, H. A.
    Dias-Santagata, D.
    Iafrate, A. J.
    Bardia, A.
    Brastianos, P. K.
    Juric, D.
    ANNALS OF ONCOLOGY, 2019, 30
  • [45] A phase 2 study of HER3-DXd in patients (pts) with metastatic breast cancer (MBC)
    Hamilton, Erika P.
    Dosunmu, Ololade
    Shastry, Mythili
    Finney, Lindsey
    Sellami, Dalila B.
    Sternberg, David W.
    Wright-Browne, Vance
    Toppmeyer, Deborah
    Gwin, William R.
    Thaddeus, J. Thaddeus
    Cultrera, Jennifer L.
    Bagegni, Nusayba Ali
    Khoury, Katia
    Heeke, Arielle Lutterman
    Yuan, Yuan
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [46] Biological and clinical effects of abemaciclib in a phase 2 neoadjuvant study for postmenopausal patients with HR+/HER2-breast cancer
    Fasching, P. A.
    Fernandez Abad, M.
    Garcia-Saenz, J. A.
    Schneeweiss, A.
    Guarneri, V.
    Colleoni, M.
    Petru, E.
    Costigan, T. M.
    Caldwell, C. W.
    Barriga, S.
    Hurvitz, S.
    Slamon, D.
    ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 : 225 - +
  • [47] nextMONARCH 1: Phase 2 study of abemaciclib plus tamoxifen or abemaciclib alone in HR+, HER2-advanced breast cancer
    Hamilton, E.
    Cortes, J.
    Dieras, V.
    Ozyilkan, O.
    Chen, S-C
    Petrakova, K.
    Manikhas, A.
    Jerusalem, G.
    Hegg, R.
    Lu, Y.
    Bear, M. M.
    Johnston, E. L.
    Martin, M.
    CANCER RESEARCH, 2019, 79 (04)
  • [48] Comparison of healthcare resource utilization and costs in women with HR+/HER2-metastatic breast cancer treated with ribociclib vs palbociclib or abemaciclib
    Balu, Sanjeev
    Burne, Rebecca
    Guerin, Annie
    Bungay, Rebecca
    Paul, Mary Lisha
    Sin, Roxana
    CANCER RESEARCH, 2021, 81 (04)
  • [49] Biological and clinical effects of abemaciclib in a phase 2 neoadjuvant study for postmenopausal patients with HR+/HER2-breast cancer
    Guarneri, V.
    Fasching, P. A.
    Fernandez Abad, M.
    Garcia-Saenz, A.
    Schneeweiss, A.
    Colleoni, M.
    Petru, E.
    Costigan, T. M.
    Caldwell, C. W.
    Barriga, S.
    Hurvitz, S.
    Slamon, D.
    ANNALS OF ONCOLOGY, 2017, 28 : 19 - 19
  • [50] Economic Burden of HR+/HER2-Metastatic Breast Cancer Among Adult Premenopausal Women
    Gauthier, Genevieve
    Gagnon-Sanschagrin, Patrick
    Guerin, Annie
    Burne, Rebecca
    Small, Tania
    Niravath, Polly
    Dalal, Anand A.
    ADVANCES IN THERAPY, 2018, 35 (04) : 503 - 514
12345